Home › Free Stock Grades › GERN
Geron Corporation (GERN) Stock Grade
GERN · Healthcare
A+
Market Cap
$880.0M
P/E Ratio
—
Revenue Growth (YoY)
+138.8%
Net Margin
-46.7%
Return on Equity
—
Dividend Yield
None
About Geron Corporation's fundamentals
Geron Corporation is a biotechnology company with a market capitalization of $880.0 million that demonstrated significant revenue growth of 138.8% year-over-year, indicating strong commercial traction. However, the company operates at a substantial loss, with a net margin of -46.7%, and reported a net loss in its latest annual statement, reflecting the typical cost structure of clinical-stage or early-commercialization biotech firms. The company does not currently pay a dividend, which is common for loss-making biotechnology companies that prioritize reinvestment in research and development.